How should we assess right ventricular function in 2008?

被引:26
作者
Coghlan, J. G. [1 ]
Davar, J. [2 ]
机构
[1] Royal Free Hosp, FRCP Dept Cardiol, London, England
[2] Royal Free Hosp, MRCP Dept Cardiol, London, England
关键词
end systolic elastance; right ventricular wall stress; mean normalised systolic ejection rate (MNSER); magnetic resonance imaging (MRI); combinable magnetic resonance (CMR); brain natriuetic peptide (BNP);
D O I
10.1093/eurheartj/sum027
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The right ventricle is neglected in clinical practice, both because it is difficult to assess and because there is a tack of awareness of the pivotal rote it plays in cardiac and pulmonary vascular diseases. Substantial progress is now being made and methods of assessing right ventricular function are beginning to be standardised and evaluated systematically in clinical studies. Clinicians need simple reproducible tests of right ventricular function to improve their management of pulmonary hypertension, carcinoid heart disease, congenital heart disease and left heart failure. Academics require robust methods of analysing the contribution of right ventricular myocardial failure to the clinical syndrome of cor-pulmonate and heart failure, so that the pathobiological processes can be resolved and optimal therapeutic approaches identified to support and improve right ventricular function in these conditions. While awaiting such developments we must recognise that current measures in clinical usage (right atrial area, right ventricular diameters, change in fractional area and right ventricular ejection times) give helpful if incomplete information, and should form part of standard echocardiographic assessment. Clinicians should also be aware of the progress in the fields of wall stress and strain rate imaging as these may welt be validated in the near future. MRI is already well recognised as the imaging technique of choice for right ventricular dysplasia and will certainty deliver to the clinician accurate assessment of right ventricular ejection fraction, mass and identification of areas of localised myocardial damage before long.
引用
收藏
页码:H22 / H28
页数:7
相关论文
共 67 条
[1]   Myocardial infarction redefined -: A consensus Document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction [J].
Alpert, JS ;
Antman, E ;
Apple, F ;
Armstrong, PW ;
Bassand, JP ;
de Luna, AB ;
Beller, G ;
Breithardt, G ;
Chaitman, BR ;
Clemmensen, P ;
Falk, E ;
Fishbein, MC ;
Galvani, M ;
Garson, A ;
Grines, C ;
Hamm, C ;
Jaffe, A ;
Katus, H ;
Kjekshus, J ;
Klein, W ;
Klootwijk, P ;
Lenfant, C ;
Levy, D ;
Levy, RI ;
Luepker, R ;
Marcus, F ;
Näslund, U ;
Ohman, M ;
Pahlm, O ;
Poole-Wilson, P ;
Popp, R ;
Alto, P ;
Pyörälä, K ;
Ravkilde, J ;
Rehnquist, N ;
Roberts, W ;
Roberts, R ;
Roelandt, J ;
Rydén, L ;
Sans, S ;
Simoons, ML ;
Thygesen, K ;
Tunstall-Pedoe, H ;
Underwood, R ;
Uretsky, BF ;
Van de Werf, F ;
Voipio-Pulkki, LM ;
Wagner, G ;
Wallentin, L ;
Wijns, W .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (03) :959-969
[2]   Pulmonary hypertension in patients with sickle cell disease: a longitudinal study [J].
Ataga, Kenneth I. ;
Moore, Charity G. ;
Jones, Susan ;
Olajide, Oludamilola ;
Strayhorn, Dell ;
Hinderliter, Alan ;
Orringer, Eugene P. .
BRITISH JOURNAL OF HAEMATOLOGY, 2006, 134 (01) :109-115
[3]   Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease -: A randomized, controlled trial [J].
Badesch, DB ;
Tapson, VF ;
McGoon, MD ;
Brundage, BH ;
Rubin, LJ ;
Wigley, FM ;
Rich, S ;
Barst, RJ ;
Barrett, PS ;
Kral, KM ;
Jöbsis, MM ;
Loyd, JE ;
Murali, S ;
Frost, A ;
Girgis, R ;
Bourge, RC ;
Ralph, DD ;
Elliott, CG ;
Hill, NS ;
Langleben, D ;
Schilz, RJ ;
McLaughlin, VV ;
Robbins, IM ;
Groves, BM ;
Shapiro, S ;
Medsger, TA ;
Gaine, SP ;
Horn, E ;
Decker, JC ;
Knobil, K .
ANNALS OF INTERNAL MEDICINE, 2000, 132 (06) :425-+
[4]   Sitaxsentan therapy for pulmonary arterial hypertension [J].
Barst, RJ ;
Langleben, D ;
Frost, A ;
Horn, EM ;
Oudiz, R ;
Shapiro, S ;
McLaughlin, V ;
Hill, N ;
Tapson, VF ;
Robbins, IM ;
Zwicke, D ;
Duncan, B ;
Dixon, RAF ;
Frumkin, LR .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 169 (04) :441-447
[5]   Natriuretic peptides, respiratory disease, and the right heart [J].
Bin Yap, L ;
Mukejee, D ;
Timms, PM ;
Ashrafian, H ;
Coghlan, JG .
CHEST, 2004, 126 (04) :1330-1336
[6]   N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism [J].
Binder, L ;
Pieske, B ;
Olschewski, M ;
Geibel, A ;
Klostermann, B ;
Reiner, C ;
Konstantinides, S .
CIRCULATION, 2005, 112 (11) :1573-1579
[7]  
Blyth KG, 2005, EUR HEART J, V26, P1993, DOI 10.1093/eurheartj/ehi328
[8]   DIRECT QUANTITATION OF RIGHT AND LEFT-VENTRICULAR VOLUMES WITH NUCLEAR-MAGNETIC-RESONANCE IMAGING IN PATIENTS WITH PRIMARY PULMONARY-HYPERTENSION [J].
BOXT, LM ;
KATZ, J ;
KOLB, T ;
CZEGLEDY, FP ;
BARST, RJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1992, 19 (07) :1508-1515
[9]   Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension [J].
Castelain, V ;
Chemla, D ;
Humbert, M ;
Sitbon, O ;
Simonneau, G ;
Lecarpentier, Y ;
Hervé, P .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 165 (03) :338-340
[10]   Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study [J].
Channick, RN ;
Simonneau, G ;
Sitbon, O ;
Robbins, IM ;
Frost, A ;
Tapson, VF ;
Badesch, DB ;
Roux, S ;
Rainisio, M ;
Bodin, F ;
Rubin, LJ .
LANCET, 2001, 358 (9288) :1119-1123